ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Merck & Co. has agreed to acquire Immune Design, a South San Francisco–based developer of vaccines and adjuvant systems, for about $300 million. Roger M. Perlmutter, head of Merck Research Laboratories, says the acquisition builds on Merck technology, such as its immuno-oncology therapy Keytruda, for harnessing the immune system to treat disease. Immune Design also brings G100, a small-molecule immuno-oncology drug candidate in clinical trials as a treatment for follicular non-Hodgkin’s lymphoma.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X